Arvinas, Inc.
NASDAQ: ARVN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Randy Teel
- Employees
- 430
- Headquarters
- New Haven, United States
- IPO year
- 2018
- Market cap
- $519.4M
- Website
- https://www.arvinas.com
Loading ARVN…
Loading profile data…Frequently asked questions about ARVN
What does Arvinas, Inc. (ARVN) do?
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degra...
Where does ARVN trade?
Arvinas, Inc. (ARVN) trades on the NASDAQ Global Select.
What sector is ARVN in?
Arvinas, Inc. (ARVN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arvinas, Inc.?
Randy Teel is the chief executive officer of Arvinas, Inc. (ARVN).
Where is Arvinas, Inc. headquartered?
Arvinas, Inc. is headquartered in United States.
Does ARVN pay a dividend?
Arvinas, Inc. (ARVN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARVN go public?
Arvinas, Inc. (ARVN) completed its initial public offering in 2018.